Effectiveness of Zoledronic Acid in the Prevention of Osteoporosis in Early Breast Cancer Patients Receiving Letrozole
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether zoledronic acid given intravenously every 6
months can prevent reduction in bone mineral density in women with early stage breast cancer
receiving adjuvant therapy with the aromatase inhibitor drug letrozole, after having received
adjuvant tamoxifen.